Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AVDL 
Avadel Pharmaceuticals PLC (AVDL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: AVDL (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $19.12
1 Year Target Price $19.12
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 17.87% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.84B USD | Price to earnings Ratio - | 1Y Target Price 19.12 |
Price to earnings Ratio - | 1Y Target Price 19.12 | ||
Volume (30-day avg) 8 | Beta 1.63 | 52 Weeks Range 6.38 - 19.06 | Updated Date 11/5/2025 |
52 Weeks Range 6.38 - 19.06 | Updated Date 11/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.02 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-05 | When - | Estimate 0.0763 | Actual - |
Profitability
Profit Margin -1.32% | Operating Margin (TTM) 13.04% |
Management Effectiveness
Return on Assets (TTM) -1.18% | Return on Equity (TTM) -3.63% |
Valuation
Trailing PE - | Forward PE 11.64 | Enterprise Value 1371816726 | Price to Sales(TTM) 8.33 |
Enterprise Value 1371816726 | Price to Sales(TTM) 8.33 | ||
Enterprise Value to Revenue 6.21 | Enterprise Value to EBITDA 174.42 | Shares Outstanding 97403364 | Shares Floating 80694935 |
Shares Outstanding 97403364 | Shares Floating 80694935 | ||
Percent Insiders 4.8 | Percent Institutions 89.99 |
Upturn AI SWOT
Avadel Pharmaceuticals PLC
Company Overview
History and Background
Avadel Pharmaceuticals PLC focuses on developing and commercializing innovative pharmaceutical products. Founded to address unmet medical needs, the company has grown through strategic acquisitions and internal development.
Core Business Areas
- Narcolepsy: Avadel focuses on developing and commercializing therapies for narcolepsy, with its primary product targeting excessive daytime sleepiness (EDS) in narcolepsy patients.
Leadership and Structure
The company is led by a management team with expertise in pharmaceuticals and drug development. The organizational structure includes research, development, commercial, and administrative functions.
Top Products and Market Share
Key Offerings
- Lumryz: Lumryz (sodium oxybate) is a once-at-bedtime extended-release formulation for narcolepsy treatment, specifically addressing EDS. Market share data is still developing, but it is positioned to compete with twice-nightly sodium oxybate products (Xyrem, Xywav) and other wakefulness-promoting agents. Key competitors include Jazz Pharmaceuticals (JAZZ).
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, regulatory scrutiny, and competition. The narcolepsy treatment market is growing due to increased awareness and diagnosis rates.
Positioning
Avadel is positioning Lumryz as a convenient alternative to existing treatments for narcolepsy.
Total Addressable Market (TAM)
The narcolepsy treatment market is estimated to be in the billions of dollars. Avadel aims to capture a significant share of this market with Lumryz.
Upturn SWOT Analysis
Strengths
- Novel drug formulation (once-nightly)
- Focus on unmet medical needs
- Strong intellectual property protection (patents)
Weaknesses
- Reliance on a single product (Lumryz)
- Commercial execution risk
- Potential for generic competition in the future
Opportunities
- Expanding indications for Lumryz
- Developing additional products for sleep disorders
- Partnerships and acquisitions
Threats
- Competition from existing narcolepsy treatments
- Regulatory challenges
- Pricing pressures
Competitors and Market Share
Key Competitors
- JAZZ
Competitive Landscape
Avadel's advantage lies in its once-nightly formulation. Jazz's dominance gives them the advantage of market share. Other players exist which makes the remaining market share.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by the development and launch of Lumryz.
Future Projections: Analyst projections depend on Lumryz sales forecasts and potential pipeline development. Refer to analyst reports for specific estimates.
Recent Initiatives: Recent initiatives include the launch of Lumryz and ongoing clinical trials.
Summary
Avadel Pharmaceuticals is primarily focused on Lumryz launch and market penetration. The success of the company hinges on the widespread adoption and sales of this single drug. They face competition from established players and need to execute their commercial strategy effectively. Monitoring market share, financial performance, and pipeline development is critical.
Similar Stocks
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data is subject to change and may not be entirely accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avadel Pharmaceuticals PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1996-06-07 | CEO & Director Mr. Gregory J. Divis Jr. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 188 | Website https://www.avadel.com |
Full time employees 188 | Website https://www.avadel.com | ||
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.